Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- Umfang
-
Online-Ressource, 1 online resource.
- Sprache
-
Englisch
- Erschienen in
-
Immunogenicity and safety of COVID-19 BNT162b2 booster vaccine in end-stage kidney disease patients receiving haemodialysis in Yogyakarta, Indonesia: a cohort prospective study ; volume:24 ; number:1 ; day:30 ; month:5 ; year:2023 ; pages:1-14 ; date:12.2023
BMC nephrology ; 24, Heft 1 (30.5.2023), 1-14, 12.2023
- Urheber
-
Puspitasari, Metalia
Sattwika, Prenali D.
Hidayat, Auliana R. P.
Wijaya, Wynne
Wardhani, Yulia
Intansari, Umi S.
Kertia, Nyoman
Purwanto, Bambang
Thobari, Jarir At
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1186/s12882-023-03218-x
- URN
-
urn:nbn:de:101:1-2023091208094736469601
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:47 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Puspitasari, Metalia
- Sattwika, Prenali D.
- Hidayat, Auliana R. P.
- Wijaya, Wynne
- Wardhani, Yulia
- Intansari, Umi S.
- Kertia, Nyoman
- Purwanto, Bambang
- Thobari, Jarir At
- SpringerLink (Online service)
Ähnliche Objekte (12)
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Yogyakarta Borobudur
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria
The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Yogyakarta Borobudur
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria
The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report
Effect of BNT162b2 booster dose on anti-SARS-CoV-2 spike trimeric IgG antibodies in seronegative individuals
Immunogenicity evaluation after BNT162b2 booster vaccination in healthcare workers
Humoral Response to Pfizer BNT162b2 Vaccine Booster in Maintenance Hemodialysis Patients
Omicron BA.1 neutralizing antibody response following Delta breakthrough infection compared with booster vaccination of BNT162b2
Yogyakarta Borobudur
Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
Assessment of the humoral response in Omicron breakthrough cases in healthcare workers who received the BNT162b2 booster
Cross-neutralizing antibody against emerging Omicron subvariants of SARS-CoV-2 in infection-naïve individuals with homologous BNT162b2 or BNT162b2(WT + BA.4/5) bivalent booster vaccination
Cost-benefit analysis of haemodialysis in patients with end-stage kidney disease in Abuja, Nigeria
The cardiovascular determinants of physical function in patients with end-stage kidney disease on haemodialysis
High SARS-CoV-2 antibody levels after three consecutive BNT162b2 booster vaccine doses in nursing home residents
Ertapenem-induced neurotoxicity in an end-stage renal disease patient on intermittent haemodialysis: a case report